HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT01813643

A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis

Medication studyAges 19–65ChinaSchizophrenia
The study in practice

Understand this study

Who could participate?

Listed age limits: 19 years to 65 years.

Listed locations
ChangshaSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateJuly 2012
Recruitment status
Terminated
Enrollment listed in the registry
50
Sponsor
Wei Hao
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
China
Age range
From 19 Years to 65 Years
Official registry ID
NCT01813643
Official title
Show the full official title

A Multiple-Center, Randomized, Double-Blind Study of Comparison of Risperidone and Aripiprazole for Treatment

Recruitment & locations

Terminated

Changsha

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Wei Hao.

Does this study involve medication?

Yes. The study involves medication, including Risperidone and Aripiprazole.

Who can participate?

Listed age limits: 19 years to 65 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies